As shown in Table 1, the greatest mortality improvement is expected in the middle-aged group (4559 years), where both uptake and cardiovascular risk intersect
So we we do have a dichotomy here of, you know, many companies wanting to cover these products because theyre theyre great drugs for the use, for the treatment of obesity, but, again, concerns about the budget impact and overall sustainability of this coverage
When injected systemically, BPC-157 migrates preferentially to areas of tissue damage throughout the body
Hospitalists play a central role in bridging acute and chronic care by initiating appropriate therapies, addressing comorbidities, and ensuring coordination with outpatient providers
Efficacy and tolerability of vildagliptin monotherapy in drug-nave patients with type 2 diabetes